Clinical Trial Update: Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating Mapatumumab in combination with Sorafenib for advanced hepatocellular carcinoma has completed recruitment with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Mapatumumab (mapatumumab)
• Sorafenib (Sorafenib)

Snippet

Sponsor: Human Genome Sciences Inc., a GSK Company | Conditions: Carcinoma, Hepatocellular | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2018-12-19